Navigation Links
Galiximab in combination with rituximab in patients with previously untreated follicular lymphoma

Lugano, Switzerland June 7, 2008 The Cancer and Leukemia Group B (CALGB) today announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab. Of the 61 patients in the study, 44 percent achieved a complete response and 26 percent had a partial response. The data were presented at the 10th International Conference on Malignant Lymphoma (ICML).

The results of this open label study suggest that adding galiximab to rituximab may be a promising regimen for patients with follicular lymphoma (FL), a common type of non-Hodgkin lymphoma (NHL), and that further study is warranted. The objective of the CALGB-coordinated study is to determine the overall response rate (ORR) and time-to-progression of the disease after treatment with a combined regimen of galiximab and rituximab. At this point, however, it is too early to assess the time-to-progression endpoint.

"Most non-Hodgkin lymphoma patients receive rituximab, either as a single agent or in combination with chemotherapy," said Myron Czuczman, M.D., Roswell Park Cancer Institute, principal investigator of this study. "Now, 'biologic' agents are being studied in combination to assess the efficacy of dual antibody therapies as potential alternatives to chemotherapy-based regimens."

Patients enrolled in the study had been diagnosed with CD20-positive FL but had not received treatment for the disease. Study patients were given galiximab plus rituximab together once a week for four weeks and then every two months for the next eight months. This "extended induction" schedule was chosen based on results from an earlier Swiss (SAKK) trial using the same schedule with single-agent rituximab. Thirteen percent of patients reported a grade 3 adverse event; no grade 4 toxicities were associated with this combination immunotherapy regimen.

Galiximab is an anti-CD80 monoclonal antibody that has been studied as a single-agent in previously treated FL and in combination with rituximab against relapsed FL. The CD80 molecule is found on the surface of activated macrophages, dendritic cells and cells from various subtypes of NHL. Galiximab's potential mechanisms of action include Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and possible immunomodulatory effects on host effector cells affecting the tumor microenvironment.


Contact: Rachi Govil
Offspring PR

Related biology news :

1. Human RecQ helicases, homologous recombination and genomic instability
2. Abnormal fat metabolism underlies heart problems in diabetic patients
3. A new radiation therapy treatment developed for head and neck cancer patients
4. Device helps patients survive, regain function til transplant
5. Diet support helps chronic kidney patients
6. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
7. Doctors learn to control their own brains pain responses to better treat patients
8. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
9. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
10. New class of drug offers hope to treatment-resistant AIDS patients
11. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Post Your Comments:
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology: